Breakthrough Drugs vs. Breaking the Bank

Jun 04, 2015
By Pharmaceutical Executive Editors

As overall healthcare costs continue to rise, biopharma companies are under increasing pressure to demonstrate the economic value of their products and justify prices. This has resulted in competing demands for innovative breakthrough medicines and healthcare cost containment. Ken Kaitin, PhD, Professor and Director, Tufts Center for the Study of Drug Development, joined Pharm Exec to discuss how this conundrum is impacting drug developers. Kaitin is chairing a forum on this issue at DIA’s upcoming 51st Annual Meeting in Washington, DC.

 
native1_300x100
lorem ipsum